1 / 89

Introduction to pharmacogenomics and personalised medicine

Introduction to pharmacogenomics and personalised medicine. Jerzy Jankowski, MD Department of Clinical Pharmacology. www.zfk.ump.edu.pl. The Relationship Between Dose and Effect. Pharmacotherapy – clinical problems Adverse Drug Reactions (ADRs).

arabella
Download Presentation

Introduction to pharmacogenomics and personalised medicine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Introduction to pharmacogenomics and personalised medicine Jerzy Jankowski, MD Department of Clinical Pharmacology

  2. www.zfk.ump.edu.pl

  3. The Relationship Between Dose and Effect

  4. Pharmacotherapy – clinical problemsAdverse Drug Reactions (ADRs) • 56% of drugs that cause ADRs are metabolized by polymorphic phase I enzymes, of which 86% are CYP P450; • only 20% of drugs associated with ADRs are substrates for non-polymorphic enzymes • ADRs cause > 100 000 deaths/y in the USA • Up to 7% of all hospital admissions in the UK and Sweden are due to ADRs • ADRs cost the US society ~US$ 100 billion

  5. Pharmacotherapy – clinical problemsEfficacy • 30-60% of subjects treated with drugs do not respond to drug therapy

  6. Pharmacogenomics Is the study of how an individual’s genetic makeup affects the body’s response to drugs. The key to creating personalised drugs with greater efficacy and safety Combines traditional pharmaceutical sciences with an understanding of common DNA variations in the human genome The most common DNA variations- SNPs

  7. Genetic polymorphisms Exist in a human population when allelic variants occure with a frequency of 1% or greater

  8. TYPES OF GENETIC VARIANTS • single nucleotide polymorphisms ( SNPs ) 1 SNP every 300 – 1000 base pairs • Insertions/deletions ( INDELS ) in comparison with SNPs, indels are much less frequent, especially in coding regions of genes • Copy number variations ( CNVs ) – large segments of DNA ( gene duplications, gene deletions, gene inversions )

  9. SINGLE NUCLEOTIDE POLYMORPHISM • SNPs in the coding region cSNPs: - non-synonymous or missense (protein strucutre, stability, substrate affinty or introduce a stop codon) - synonymous or sense (transcript stability, splicing) • Noncoding SNPs may occur in 3´ and 5´ UTR, in promoter or enhancer regions, in introns or in intergenic regions

  10. MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS

  11. ETHNIC DIVERSITY • Polymorphisms differ in their frequencies within human populations • Polymorphisms are classified as: - cosmopolitan ( present in all ethnic group ) - population specific ( or ethnic and race ) • The presence of ethnic and race - specific polymorphisms are consistent with geographical isolation of human populations

  12. Pharmacogenomics SNPs are often linked to an individual’s response to a drug.

  13. Anticipated benefits of pharmacogenomics • More powerful medicine Drugs more targeted to specific diseases, maximising therapeutic effects while decreasing damage to nerby healthy cells • Better, safer drugs the First Time The best available drug therapy from the beginning; shorter recovery time; the likelikehood of adverse reactions is eliminated

  14. Anticipated benefits of pharmacogenomics • More accurate methods of determinig appropriate drug dosages Current methods of basing dosages on weight and age will be replaced with dosages based on person’s genetics • Advanced screening for disease Treatments can be introduced at the most appropriate stage to maximize their therapy

  15. Anticipated benefits of pharmacogenomics • Better vaccines Made of either DNA or RNA, promise all the benefits of existing vaccines without all the risks • Improvements in the drug discovery and approval process The cost and risk of clinical trials will be reduced by targeting only those persons capable of responding to a drug • Decrease in the overall cost of health care

  16. The fate of a drug in the body Is affected by: Liberation Absorption Distribution Metabolism Excretion LADME

  17. PHASE I AND PHASE II REACTIONS IN DRUG DYSPOSITION

  18. Pathways of drug metabolism • Phase I reactions: oxidation reduction hydrolysis • Phase II reactions: glucuronidiation sulfation acetylation methylation

  19. PHASE I REACTIONS convert the parent drug to a more polar (water-soluble) and/ or more reactive product by unmasking or inserting a polar group such as -OH, -SH, -NH2

  20. PHASE II REACTIONS increase water solubility by conjugation of the drug molecule with a polar moiety such as glucuronate, sulfate, acete, glutathione, glycine and methyl groups

  21. Both types of reaction convert relatively lipid- soluble original drug molecules into more water-soluble metabolites that are more easily excreted.

  22. biological: gender age renal and liver fun. disease- related fac. lifestyle: smoking alkohol consumtion diet drug -drug interaction inherited Determinants of drug biotransformation

  23. GENETIC CONTRIBUTION TO PK PARAMITERS 75 – 85%

  24. Determinants of drug biotransformation • The potential risk factors of drug inefficacy and toxicity • Differences in drug metabolism can lead to severe toxicity or therapeutic failure

  25. Determinants of drug biotransformation Of greater importance are inherited determinants that affect the kinetics and dynamics of numerous drugs.

  26. Pharmacokinetic variability Refers to variability in delivery of drug to, or removal from, key molecular sits of action that mediate efficacy and/or toxicity. Drug- metabolising enzymes (DMEs) and drug transportes (P-gp) are involved in this processes.

  27. Pharmacodynamic variability refers to variable drug effects despite equivalent drug delivery to molecular sits of action. This may reflect variability in the function of the drug targets (receptors or enzymes)

  28. Genetic variation in genes for DMEs, drug receptors (DR) and drug transportes (DT) is associated with variability in efficacy and toxicity of drugs

  29. The fate of drug in the body • The majority of pharmacogenomic differences represent variability in drug metabolism • Most of the remaining represent alternations in: • Receptors • Transporters • Protein binding • Pharmacogenetic differences in absorption or excrition of drugs are relatively uncommon

  30. Polygenic Determinants of Drug Effects

  31. The phenotypes of drug metabolism • The extensive metabolizer(EM) (dominant trait; inherited as either homozygous or heterozygous for the wild- type allele (wt) • The poor metabolizer(PM) recessive autosomal trait due to mutation and/or deletion of both allels; inherited as either homozygous or heterozygous for mutant allele • The ultra- extensive metabolizer (UEM) recessive autosomal trait due to gene amplification

  32. Metabolism of Debrisoquin

  33. Cytochrome P450 (CYP450) enzymes • The most important enzymatic system • Biosynthesis and degradation of endogenous compounds (steroids, lipids, vitamines) • Degradation of exogenous compounds (diet, environment, medications) • Highly polymorphic

  34. Clasiffication of CYP450 enzymes • Amino acid similarities • Designated by a family number, a subfamily letter, a number of an individual enzyme within the subfamily and an asterisk followed by a number and a letter for each genetic (allelic) variant • www.imm.ki.se/CYPalleles/

  35. CYP 450 ENZYMES

  36. Cytochrome P450 (CYP450) enzymes • 57 CYP450 genes • CYP1, CYP2, CYP3 families appear to contribute to the metabolism of drugs • These CYP enzymes are involved in approximately 80% of oxidative drug metabolism and account for 50% of the overall elimination of commonly used drugs

  37. Cytochrom P450 3A (CYP 3A) • 3A4, 3A5, 3A7 and 3A43 isoenzymes in adults • Chromosom 7q22.1 • Probably the most important of all DMEs • Aboundant in intestinal epithelium and in the liver • 50% of the CYP450 activity in the liver • Involved in the metabolism of more then half drugs that undergo oxidation

  38. Drug interactions involving inhibition of CYP 3A

  39. Drug interactions involving inhibition of CYP 3A • The interaction between grapefruit juice nad CYP 3A substrates • 250ml of this juice inhibits intestinal CYP 3A for 24- 48h. • Grapefruit juice is contraindicated when drugs extensively metabolised by CYP 3A are used • CYP 3A inhibition is reversible 2-3 days

  40. Drug interactions involving inhibition of CYP 3A • The problem of drug interactions can be serious • For exapmle: interaction of erythromycin and inhibitory drugs (nitroimidazole, diltiazem, verapamil, troleandomycin) • When an orally administered drug undergoes extensive first-pass metabolism, its bioavailability in the face of CYP3A inhibition may increase severalfold, thus prolonging the presence of the drug in the body

  41. Cytochrom P450 3A (CYP 3A) • Activity vary markedly among individuals of a given population • Multiple genes are involved in its regulation • Activity modulated by several factors including drugs • Drug interactions may increase or reduce CYP 3A activity (expanding the range of variablility to about 400-fold)

  42. Cytochrom P450 3A (CYP 3A) • Variability in drug levels of this magnitude, potentially presents a major therapeutic problem in dosage optimization. • For example: dosage of cyclosporine in patiens receiving also ketoconazole • For example: dosage of cyclosporine in patients receiving also rifampin

  43. Drug interactions involving induction of CYP 3A • The induction of CYP 3A significantlly decreases (up to 95%) the plasma levels of certain drugs administered concurrently • CYP 3A activity is especially sesnitive to modulation • Previously effective drug dosages become ineffective

  44. Drug interactions involving induction of CYP 3A • The consequences of CYP 3A induction are not immediate • Steady- state levels are reached in 2-3 weeks • „Washing out” the induction effect also takes several weeks • Effectivnes of drug therapy is reduced

More Related